Low dosage of levomepromazine did not increase plasma concentrations of fluvoxamine

International Clinical Psychopharmacology

Volumn 15, Issue 4, 2000, Pages 233-235

  Yoshimura, Reiji ^a   Ueda, N ^a   Nakamura, J ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Fluvoxamine; Levomepromazine; Plasma concentration

Indexed keywords

CYTOCHROME P450; FLUVOXAMINE; LEVOMEPROMAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FEMALE; HUMAN; INSOMNIA; MALE; PANIC; PRIORITY JOURNAL;

EID: 0033917570     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015040-00007     Document Type: Article

References (13)

1. Balant-Gorgia AE, Balant LP, Genet CH, Dayer P, Aeschlimann JM, Garrone G (1986) Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 31:449-455.
2. Benfield P, Ward A (1986) Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32:313-334.
3. Brøsen K, Zengin T, Meyer UA (1991) Role of 450 IID6, the target of the sparteine/debrisoquine oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 4:609-617.
4. Carrillo JA, Dahl M-L, Svensson J-O, Alm C, Rodríguez I, Bertilsson L (1996) Disposition of fluvoxamine in human is determined by polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 60:183-190.
5. Derenne F, Joanne C, Vandél S, Bertschy G, Volmat R, Bechtel P (1989) Debrisoquine oxidation phenotyping and psychiatric drug treatment. Eur J Clin Pharmacol 36:53-58.
6. De Wilde JEM, Doogan DP (1982) Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 4:249-259.
7. Loennechen T, Andersen A, Hals PA, Dahl SG (1990) High-performance liquid chromatographic determination of levomepromazine (methotrimeprazine) and its main metabolites in serum and urine. Ther Drug Monit 12:574-581.
8. Overmars H, Scherpenisse PM, Post LC (1983) Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet 8:269-280.
9. Palmer KJ, Benfield P (1994) Fluvoxamine: an overview of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. CNS Drugs 1:57-87.
10. Perucca E, Gatti G, Spina E (1994) Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 27:175-190.
11. Spigset O, Granberg K, Hägg A, Norström A, Dahlqvist R (1997) Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphism. Eur J dm Pharmacol 52:129-133.
12. Sylvälahti E, Lindberg R, Kallio J, De Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22:89-92.
13. Van der Meersch-Mougeot V, Diquet B (1991) Sensitive one-step extraction procedure for column liquid chroatographc determination of fluvoxamine in human and rat plasma. J Chromatogr 567:441-449.